Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next days. Integer Holdings has gained 28.5% compared with the industry’s 4.2% rise in the past year. When you see ZBH stock appear in the results, tap it to open up the purchase screen. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. New daily records for COVID-19 cases and hospitalizations mean these stocks are probably headed in opposite directions.
- While still sporting a modest year-to-date loss, the S&P 500 Health Care Index is higher by 4.44% over the past month, and with the healthcare sector’s reputation for defensive and quality traits, it …
- With its acquisitions of Centerpulse in 2003 and Biomet in 2015, the company holds a commanding share of the reconstructive market in the United States, Europe, and Japan.
- Second quarter net sales of $1.870 billion increased 4.9% and 6.0% on a constant currency1 basis Second quarter diluted earnings per share were $1.00; adjusted1 diluted earnings per share were $1.82 C…
- Integer Holdings has gained 28.5% compared with the industry’s 4.2% rise in the past year.
The Zacks Consensus Estimate for Zimmer Biomet’s 2023 earnings per share (EPS) has increased from $7.45 to $7.51 in the past 90 days. Given that Zimmer Biomet Holdings is relatively undervalued, the long-term return of its stock is likely to be higher than its business growth. One share of ZBH stock can currently be purchased for approximately $112.22. Zimmer Biomet’s stock performance has been mixed over the past few years. In early 2020, the company’s stock price experienced a sharp decline due to the COVID-19 pandemic, but since then, it has rebounded and continues to experience volatility. The musculoskeletal healthcare company continues to try to turn things around, with limited success in the first quarter.
The leading musculoskeletal healthcare company has a market capitalization of $23.50 billion. The company has an earnings yield of 6.78% against the industry’s -1.62%. Zimmer Biomet surpassed estimates in three of the trailing four quarters and was breakeven in one, delivering an average earnings surprise of 4.47%. Zimmer Biomet Holdings Inc is a medical technology company that designs, develops and manufactures a wide range of orthopedic and musculoskeletal products. With headquarters in Warsaw, Indiana, the company was formed in 2015 after the merger of Zimmer Holdings and Biomet Inc, two of the world’s leading companies in the orthopedic industry. Zimmer Biomet’s mission is to help people alleviate pain, regain mobility and improve the quality of life for patients worldwide.
Zimmer Biomet Holdings Inc Analysis
Zimmer Biomet Holdings has been profitable 8 times over the past 10 years. Over the past twelve months, the company had a revenue of $7.20 billion and Earnings Per Share (EPS) of $2.41. Its operating margin is 18.69%, ranking better than 82.3% of 836 companies in the Medical Devices & Instruments industry. Overall, Zimmer Biomet Holdings’ profitability Luxury stock is ranked 7 out of 10, indicating fair profitability. The GF Value is a proprietary measure that represents the current intrinsic value of a stock. It is calculated based on historical trading multiples, a GuruFocus adjustment factor derived from the company’s past performance and growth, and future business performance estimates.
- It is calculated based on historical trading multiples, a GuruFocus adjustment factor derived from the company’s past performance and growth, and future business performance estimates.
- While the company is one of the most significant players in the orthopedic industry, it faces competition from other established companies and new entrants.
- To maintain its market position, Zimmer Biomet must continue to innovate and invest in research and development.
- Based on an average daily trading volume, of 1,500,000 shares, the short-interest ratio is presently 1.4 days.
- Zimmer Biomet Holdings has been profitable 8 times over the past 10 years.
- Given that Zimmer Biomet Holdings is relatively undervalued, the long-term return of its stock is likely to be higher than its business growth.
Based on an average daily trading volume, of 1,500,000 shares, the short-interest ratio is presently 1.4 days. Finally, changes in consumer preferences and healthcare trends could impact demand for Zimmer Biomet’s products. For example, the increasing popularity of non-surgical treatments for orthopedic conditions could affect the demand for joint replacement products. According to 20 analysts, the average rating for ZBH stock is “Hold.” The 12-month stock price forecast is $138.77, which is an increase of 23.66% from the latest price. Recent stocks from this report have soared up to +178.7% in 3 months – this month’s picks could be even better.
If the ROIC exceeds the WACC, the company is likely creating value for its shareholders. During the past 12 months, Zimmer Biomet Holdings’ ROIC was 5.05 while its WACC came in at 7.57. 16 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Zimmer Biomet in the last year.
The issuers of these securities may be an affiliate of Public, and Public (or an affiliate) may earn fees when you purchase or sell Alternative Assets. For more information on risks and conflicts of interest, see these disclosures. No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC.
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.17% per year.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. The Zacks Consensus Estimate for the company’s 2023 revenues is pegged at $7.40 billion. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer.
Services
A great way to understand a company’s financial strength is by looking at its cash-to-debt ratio and interest coverage. Zimmer Biomet Holdings has a cash-to-debt ratio of 0.05, ranking worse than 95.6% of 841 companies in the Medical Devices & Instruments industry. Its overall financial strength is 6 out of 10, indicating fair financial health. Zimmer Biomet updated its FY 2023 earnings guidance on Wednesday, September, 20th. The company provided earnings per share (EPS) guidance of $7.47-$7.57 for the period, compared to the consensus EPS estimate of $7.50.
ZBH Zimmer Biomet Holdings Inc
All regions benefited from continued recovery of elective procedures, backlog recapture and strong commercial execution and new product uptake. Before investing in a company, it’s crucial to assess its financial strength. Companies with poor financial strength pose a higher risk of permanent loss.
Zimmer Biomet Announces Second Quarter 2023 Financial Results
As elective surgery candidates return to operating rooms, revenue will ramp up. While still sporting a modest year-to-date loss, the S&P 500 Health Care Index is higher by 4.44% over the past month, and with the healthcare sector’s reputation for defensive and quality traits, it … Company’s seventh sustainability report highlights progress in product quality & safety, environmental impact improvements and diversity, equity and inclusion initiatives WARSAW, Ind. , May 2, 2023 /P…
Zimmer Biomet Announces Key Updates to Company’s Executive Leadership Team
The GF Value Line gives an overview of the ideal trading value of the stock. One of the most significant risks facing Zimmer Biomet is the potential for regulatory changes that could impact the industry. Changes in regulatory requirements could increase the costs and time required to bring new products to market, affecting Zimmer Biomet’s ability to innovate and compete.
Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Zimmer how to read forex charts Biomet saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 2,170,000 shares, a decrease of 20.2% from the August 15th total of 2,720,000 shares.
Ozempic Is All the Rage. And That Might Explain a Mysterious Stock Selloff.
There are currently 2 sell ratings, 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “hold” ZBH shares. candle pattern forex A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZBH, but not buy additional shares or sell existing shares.
The “Halftime Report” traders give their top picks to watch for the second half.
These returns cover a period from January 1, 1988 through September 4, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.